PM
MCID: PLY041
MIFTS: 52

Polymyositis (PM) malady

Categories: Rare diseases, Neuronal diseases, Nephrological diseases, Bone diseases, Respiratory diseases

Aliases & Classifications for Polymyositis

Aliases & Descriptions for Polymyositis:

Name: Polymyositis 50 51 56 52 69
Pm 56

Characteristics:

Orphanet epidemiological data:

56
polymyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (Argentina),1-9/100000 (Argentina),1-9/1000000 (Australia),1-9/100000 (Australia),1-9/1000000 (Spain),1-9/1000000 (Sweden); Age of onset: Adult,Elderly; Age of death: adult;

Classifications:



External Ids:

Orphanet 56 ORPHA732
MESH via Orphanet 43 D017285
UMLS via Orphanet 70 C0085655
ICD10 via Orphanet 34 M33.2
ICD10 33 M33.2

Summaries for Polymyositis

NINDS : 51 Polymyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness.  Polymyositis affects skeletal muscles (those involved with making movement) on both sides of the body.  It is rarely seen in persons under age 18; most cases are in adults between the ages of 31 and 60.  Progressive muscle weakness starts in the proximal muscles (muscles closest to the trunk of the body) which eventually leads to difficulties climbing stairs, rising from a seated position, lifting objects, or reaching overhead.  People with polymyositis may also experience arthritis, shortness of breath, difficulty swallowing and speaking, and heart arrhythmias.  In some cases of polymyositis, distal muscles (muscles further away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses.  Polymyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus.  Polymyositis may also be associated with infectious disorders, such as HIV-AIDS.

MalaCards based summary : Polymyositis, also known as pm, is related to myocardial infarction and juvenile polymyositis, and has symptoms including abnormality of the renal tubule, chondrocalcinosis and muscular hypotonia. An important gene associated with Polymyositis is HARS (Histidyl-TRNA Synthetase), and among its related pathways/superpathways are Fluid shear stress and atherosclerosis and Interleukin-4 and 13 signaling. The drugs Abatacept and Pirfenidone have been mentioned in the context of this disorder. Affiliated tissues include lung, skeletal muscle and heart, and related phenotype is Decreased shRNA abundance (Z-score < -2).

NIH Rare Diseases : 50 polymyositis is a type of inflammatory myopathy, which refers to a group of muscle diseases characterized by chronic muscle inflammation and weakness. it involves skeletal muscles (those involved with making movement) on both sides of the body. although it can affect people of all ages, most cases are seen in adults between the ages of 31 and 60. the exact cause of polymyositis is unknown; however, the disease shares many characteristics with autoimmune disorders which occur when the immune system mistakenly attacks healthy body tissues. it some cases, the condition may be associated with viral infections, malignancies, or connective tissue disorders. although there is no cure for polymyositis, treatment can improve muscle strength and function. last updated: 9/9/2015

Wikipedia : 71 Polymyositis (PM) is a type of chronic inflammation of the muscles (inflammatory myopathy) related to... more...

Related Diseases for Polymyositis

Diseases in the Polymyositis family:

Juvenile Polymyositis

Diseases related to Polymyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 224)
id Related Disease Score Top Affiliating Genes
1 myocardial infarction 28.4 CHKB ICAM1 MB VCAM1
2 juvenile polymyositis 12.1
3 dermatomyositis 11.7
4 myositis 11.3
5 mixed connective tissue disease 11.2
6 idiopathic inflammatory myopathy 11.1
7 tropical spastic paraparesis 11.1
8 antisynthetase syndrome 11.1
9 myelopathy, htlv-1-associated 10.7
10 retrovirus-associated myelopathy 10.7
11 childhood type dermatomyositis 10.7
12 aplasia cutis autosomal recessive 10.3 HARS KARS
13 lung disease 10.2
14 interstitial lung disease 10.2
15 hypopyon ulcer 10.1 ICAM1 VCAM1
16 macrodactyly of the foot 10.1 ICAM1 VCAM1
17 ependymoblastoma 10.1 ICAM1 VCAM1
18 inclusion body myositis 10.1
19 hypotrichosis 4 10.1 ICAM1 IL1A
20 right ventricle hypoplasia 10.1 ICAM1 VCAM1
21 phlegmonous dacryocystitis 10.1 ICAM1 VCAM1
22 stomach carcinoma in situ 10.1 AARS IL1A
23 renovascular hypertension 10.1 IL1A VCAM1
24 vaginal endometrial stromal tumor 10.1 ICAM1 VCAM1
25 spastic hemiplegia 10.1 ICAM1 IL1A
26 ovarian clear cell malignant adenofibroma 10.0 ICAM1 VCAM1
27 dislocation of ear ossicle 10.0 ICAM1 VCAM1
28 conjunctivochalasis 10.0 SFTPD VCAM1
29 myopathy 10.0
30 myopathy, distal, tateyama type 10.0 CHKB MB
31 short stature, developmental delay, and congenital heart defects 10.0 CHKB MB
32 chromophobe renal cell carcinoma 10.0 AARS GARS HARS KARS
33 pneumonia 10.0
34 arthritis 10.0
35 chorea gravidarum 10.0 CHKB MB
36 perrault syndrome 10.0 ICAM1 VCAM1
37 rheumatoid arthritis 10.0
38 hepatitis 9.9
39 lymphedema 9.9 ICAM1 IL1A VCAM1
40 orofacial granulomatosis 9.9 ICAM1 IL1A VCAM1
41 limbal stem cell deficiency 9.9 IL1A VCAM1
42 bare lymphocyte syndrome, type i 9.9 ICAM1 IL1A VCAM1
43 infiltrating ureter transitional cell carcinoma 9.9 CHKB MB
44 lymphoma 9.8
45 lupus erythematosus 9.8
46 myocarditis 9.8
47 connective tissue disease 9.8
48 systemic lupus erythematosus 9.8
49 periosteal chondrosarcoma 9.8 ICAM1 MB VCAM1
50 thymoma 9.8

Comorbidity relations with Polymyositis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Dermatomyositis Heart Disease
Hypertension, Essential Hypothyroidism
Osteoporosis Temporal Arteritis

Graphical network of the top 20 diseases related to Polymyositis:



Diseases related to Polymyositis

Symptoms & Phenotypes for Polymyositis

Human phenotypes related to Polymyositis:

56 32 (show all 42)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the renal tubule 56 32 Occasional (29-5%) HP:0000091
2 chondrocalcinosis 56 32 Occasional (29-5%) HP:0000934
3 muscular hypotonia 56 32 Very frequent (99-80%) HP:0001252
4 gait disturbance 56 32 Occasional (29-5%) HP:0001288
5 reduced tendon reflexes 56 32 Occasional (29-5%) HP:0001315
6 arthritis 56 32 Frequent (79-30%) HP:0001369
7 dysphonia 56 32 Occasional (29-5%) HP:0001618
8 abnormality of the mitral valve 56 32 Occasional (29-5%) HP:0001633
9 congestive heart failure 56 32 Occasional (29-5%) HP:0001635
10 hypertrophic cardiomyopathy 56 32 Occasional (29-5%) HP:0001639
11 dilated cardiomyopathy 56 32 Occasional (29-5%) HP:0001644
12 myocardial infarction 56 32 Occasional (29-5%) HP:0001658
13 pericarditis 56 32 Occasional (29-5%) HP:0001701
14 weight loss 56 32 Frequent (79-30%) HP:0001824
15 fever 56 32 Frequent (79-30%) HP:0001945
16 constipation 56 32 Frequent (79-30%) HP:0002019
17 gastroesophageal reflux 56 32 Occasional (29-5%) HP:0002020
18 abdominal pain 56 32 Occasional (29-5%) HP:0002027
19 anorexia 56 32 Frequent (79-30%) HP:0002039
20 respiratory insufficiency 56 32 Frequent (79-30%) HP:0002093
21 pulmonary fibrosis 56 32 Occasional (29-5%) HP:0002206
22 gastrointestinal hemorrhage 56 32 Occasional (29-5%) HP:0002239
23 hepatomegaly 56 32 Occasional (29-5%) HP:0002240
24 vasculitis 56 32 Occasional (29-5%) HP:0002633
25 arthralgia 56 32 Very frequent (99-80%) HP:0002829
26 exertional dyspnea 56 32 Frequent (79-30%) HP:0002875
27 autoimmunity 56 32 Very frequent (99-80%) HP:0002960
28 breast carcinoma 56 32 Occasional (29-5%) HP:0003002
29 elevated serum creatine phosphokinase 56 32 Very frequent (99-80%) HP:0003236
30 myalgia 56 32 Frequent (79-30%) HP:0003326
31 emg abnormality 56 32 Very frequent (99-80%) HP:0003457
32 proximal muscle weakness 56 32 Very frequent (99-80%) HP:0003701
33 abnormality of muscle fibers 56 32 Very frequent (99-80%) HP:0004303
34 venous thrombosis 56 32 Occasional (29-5%) HP:0004936
35 abnormal atrioventricular conduction 56 32 Occasional (29-5%) HP:0005150
36 fatigue 56 32 Frequent (79-30%) HP:0012378
37 elevated aldolase level 56 32 Very frequent (99-80%) HP:0012544
38 cough 56 32 Very frequent (99-80%) HP:0012735
39 abnormality of the voice 56 Occasional (29-5%)
40 interstitial pulmonary disease 56 Frequent (79-30%)
41 arrhythmia 56 Occasional (29-5%)
42 interstitial pulmonary abnormality 32 HP:0006530

GenomeRNAi Phenotypes related to Polymyositis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 9.58 GARS
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.58 IARS KARS
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.58 GARS
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.58 KARS
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 9.58 GARS IARS KARS
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.58 GARS
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.58 IARS
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.58 IARS
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.58 KARS
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 9.58 KARS
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.58 KARS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 9.58 GARS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.58 GARS
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.58 KARS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 9.58 GARS

Drugs & Therapeutics for Polymyositis

Drugs for Polymyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 119)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
2
Pirfenidone Investigational Phase 4 53179-13-8 40632
3 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
4 Hormones Phase 4,Phase 3,Phase 2,Phase 1
5 Vaccines Phase 4
6 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
8 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
9 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
11 beta-endorphin Phase 4,Phase 2
12 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
13 Adrenocorticotropic Hormone Phase 4,Phase 2
14 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
15 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1
16 Melanocyte-Stimulating Hormones Phase 4,Phase 2
17
Cyclosporine Approved, Investigational, Vet_approved Phase 3 79217-60-0, 59865-13-3 5284373 6435893
18
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492
19
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
20
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
21
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
22
Benzocaine Approved Phase 2, Phase 3 1994-09-7, 94-09-7 2337
23
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
24
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
25
Levoleucovorin Approved Phase 3,Phase 2 68538-85-2
26
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
27
Alendronate Approved Phase 3 121268-17-5, 66376-36-1 2088
28
Etanercept Approved, Investigational Phase 2, Phase 3,Phase 1 185243-69-0
29
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
30
Infliximab Approved Phase 2, Phase 3 170277-31-3
31
belimumab Approved Phase 2, Phase 3 356547-88-1 5957 10451420
32
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
33
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 54575, 6560146 143
34 tannic acid Approved, Nutraceutical Phase 2, Phase 3
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
36
Alfacalcidol Approved, Nutraceutical Phase 3 41294-56-8 5282181
37 Prednisolone acetate Phase 2, Phase 3
38 glucocorticoids Phase 3,Phase 2,Phase 1
39 Folic Acid Antagonists Phase 3,Phase 2
40 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
41 Neuroprotective Agents Phase 3,Phase 2
42 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
43 Dermatologic Agents Phase 3,Phase 2
44 Vitamin B Complex Phase 3,Phase 2
45 Immunoglobulins Phase 3,Phase 2,Phase 1,Early Phase 1
46 Prednisolone hemisuccinate Phase 2, Phase 3
47 Prednisolone phosphate Phase 2, Phase 3
48 Anti-Infective Agents Phase 3,Phase 2,Phase 1
49 Protective Agents Phase 3,Phase 2
50 Antiemetics Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 75)
id Name Status NCT ID Phase
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4
3 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4
4 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4
5 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Not yet recruiting NCT02821689 Phase 4
6 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Unknown status NCT00504348 Phase 2, Phase 3
7 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3
8 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3
9 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3
10 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3
11 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3
12 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3
13 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3
14 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3
15 Belimumab in Myositis Recruiting NCT02347891 Phase 2, Phase 3
16 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Recruiting NCT02728752 Phase 3
17 A Clinical Trial for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3
18 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3
19 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2
20 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed NCT01906372 Phase 2
21 Methimazole to Treat Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2
22 Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2
23 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
24 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2
25 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2
26 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2
27 Safety and Efficacy of BAF312 in Dermatomyositis Completed NCT02029274 Phase 2
28 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Completed NCT01572844 Phase 2
29 Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis Completed NCT00005571 Phase 2
30 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2
31 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Recruiting NCT02043548 Phase 2
32 Study of IFN-K in Dermatomyositis Recruiting NCT02980198 Phase 2
33 Trial of IMO-8400 in Adult Patients With Dermatomyositis Recruiting NCT02612857 Phase 2
34 Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis Recruiting NCT02466243 Phase 2
35 A Study In Adults With Moderate To Severe Dermatomyositis Not yet recruiting NCT03181893 Phase 2
36 Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders Not yet recruiting NCT02418273 Phase 1, Phase 2
37 Efficacy and Tolerability of BAF312 in Patients With Polymyositis Terminated NCT01801917 Phase 2
38 Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis Terminated NCT01148810 Phase 2
39 Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis Unknown status NCT00230204 Phase 1
40 A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis Completed NCT00533091 Phase 1
41 Mycophenolate Mofetil in Systemic Sclerosis Completed NCT00433186 Phase 1
42 A Pilot Study of Etanercept in Dermatomyositis Completed NCT00112385 Phase 1
43 Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders Completed NCT00010335 Phase 1
44 A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases Recruiting NCT02780674 Phase 1
45 Study of Tofacitinib in Refractory Dermatomyositis Recruiting NCT03002649 Phase 1
46 Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia Unknown status NCT01482494
47 A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy Unknown status NCT00971828
48 Creatine Supplementation in Pediatric Rheumatology Unknown status NCT01217320
49 Study of the Prevalence of Polymyositis and Dermatomyositis in Normandy Completed NCT02880527
50 Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis Completed NCT01813617

Search NIH Clinical Center for Polymyositis

Genetic Tests for Polymyositis

Anatomical Context for Polymyositis

MalaCards organs/tissues related to Polymyositis:

39
Lung, Skeletal Muscle, Heart, T Cells, Breast, Bone, Testes

Publications for Polymyositis

Articles related to Polymyositis:

(show top 50) (show all 784)
id Title Authors Year
1
Juvenile dermatomyositis/polymyositis and lymphoma. ( 28477693 )
2017
2
Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients. ( 28283597 )
2017
3
Anti-SS-A/Ro antibody positivity as a risk factor for relapse in patients with polymyositis/dermatomyositis. ( 28463039 )
2017
4
Positive Association between ANKRD55 Polymorphism 7731626 and Dermatomyositis/Polymyositis with Interstitial Lung Disease in Chinese Han Population. ( 28470010 )
2017
5
Polymyositis without Beneficial Response to Steroid Therapy: Should Miyoshi Myopathy be a Differential Diagnosis? ( 28053302 )
2017
6
Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. ( 28012490 )
2017
7
Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. ( 27761751 )
2016
8
Analysis of sexual function of patients with dermatomyositis and polymyositis through self-administered questionnaires: a cross-sectional study. ( 27865559 )
2016
9
Polymyositis with pulmonary and renal involvement refractory to combined immunosuppressive therapy treated with rituximab. ( 27156519 )
2016
10
Altered mean platelet volume in patients with polymyositis and its association with disease severity. ( 27191605 )
2016
11
Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis. ( 27588444 )
2016
12
Fatty acid binding protein 3 is associated with skeletal muscle strength in polymyositis and dermatomyositis. ( 26891180 )
2016
13
Estrogen Downregulates miR-21 Expression and Induces Inflammatory Infiltration of Macrophages in Polymyositis: Role of CXCL10. ( 26873848 )
2016
14
Paraneoplastic polymyositis presenting as a clinically occult breast cancer. ( 27659377 )
2016
15
Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. ( 27330809 )
2016
16
Do Muscle Enzyme Changes Forecast Liver Injury in Polymyositis/Dermatomyositis Patients Treated with Methylprednisolone and Methotrexate? ( 27312550 )
2016
17
CD4+ and CD8+ CD28null T cells are Cytotoxic to Autologous Muscle Cells in Polymyositis Patients. ( 26895511 )
2016
18
IL-15 up-regulates the MMP-9 expression levels and induces inflammatory infiltration of macrophages in polymyositis through regulating the NF-kB pathway. ( 27374114 )
2016
19
Case of anti-RuvBL1/2 antibody-positive morphea and polymyositis. ( 27786369 )
2016
20
Polymyositis anti-SRP antibodies and pregnancy about 2 cases. ( 27795789 )
2016
21
Successful use of rituximab in a patient with refractory thrombotic thrombocytopaenic purpura complicated by polymyositis. ( 27309121 )
2016
22
Polymyositis in a patient with ulcerative colitis. ( 27032754 )
2016
23
MiR-146a Regulates Inflammatory Infiltration by Macrophages in Polymyositis/Dermatomyositis by Targeting TRAF6 and Affecting IL-17/ICAM-1 Pathway. ( 27889748 )
2016
24
A case of polymyositis. ( 27728693 )
2016
25
Unilateral temporal myositis heralding polymyositis: ultrasonographic and elastographic findings. Case report. ( 26962566 )
2016
26
Increased Expression of the NOD-like Receptor Family, Pyrin Domain Containing 3 Inflammasome in Dermatomyositis and Polymyositis is a Potential Contributor to Their Pathogenesis. ( 27098789 )
2016
27
Sarcoid Myositis with Anti-Ku Antibody Consistent with both Sarcoidosis and Polymyositis. ( 27477413 )
2016
28
Serum level of DNase1l3 in patients with dermatomyositis/polymyositis, systemic lupus erythematosus and rheumatoid arthritis, and its association with disease activity. ( 28039554 )
2016
29
The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis. ( 27502600 )
2016
30
Platelet to Lymphocyte Ratio in Polymyositis as a Marker of Disease Activity. ( 27349019 )
2016
31
Current Perspectives on Imaging for Systemic Lupus Erythematosus, Systemic Sclerosis, and Dermatomyositis/Polymyositis. ( 27742023 )
2016
32
Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. ( 27888997 )
2016
33
Myasthenic crisis and polymyositis induced by one dose of nivolumab. ( 27420474 )
2016
34
Risk of Malignancy in Dermatomyositis and Polymyositis: A Systematic Review and Meta-Analysis. ( 27534779 )
2016
35
Patients with Systemic Sclerosis/polymyositis Overlap Have a Worse Survival Rate Than Patients Without It. ( 27528573 )
2016
36
Mixed Connective Tissue Disorder Complicated by Polymyositis, Sjogren's Syndrome, Pleural Effusion and Pericarditis. ( 28083450 )
2016
37
Tuberculous Fasciitis in Polymyositis: A Rare Case of Extrapulmonary Tuberculosis. ( 27803421 )
2016
38
Do dermatomyositis and polymyositis affect similar thigh muscles? A comparative MRI-based study. ( 27991408 )
2016
39
Activation of the wnt/I^-Catenin Signaling Pathway in Polymyositis, Dermatomyositis and Duchenne Muscular Dystrophy. ( 27165423 )
2016
40
A potential clinical usefulness of measuring serum bilirubin levels in patients with polymyositis. ( 26957263 )
2016
41
Gene Expression Profile of Inflammatory Myopathy with Malignancy is Similar to that of Dermatomyositis rather than Polymyositis. ( 27629949 )
2016
42
Lymphomatoid Granulomatosis with Paraneoplastic Polymyositis: A Rare Malignancy with Rare Complication. ( 26966605 )
2016
43
Laryngeal carcinoma presenting as polymyositis: A paraneoplastic syndrome. ( 27011653 )
2016
44
Dysfunction of endothelial progenitor cells is associated with the type I IFN pathway in patients with polymyositis and dermatomyositis. ( 27498356 )
2016
45
The risk of cancer in patients with connective tissue diseases but without dermatomyositis or polymyositis: A multicenter cohort study conducted over 15 years in China. ( 27474413 )
2016
46
Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Physical Dysfunction after Treatment in Polymyositis and Dermatomyositis: An Observational Study of Physical Dysfunction with Myositis in Japan. ( 26925419 )
2016
47
Plasma Kinetics of Th1, Th2 and Th17 Cytokines in Polymyositis Related to Chronic Graft-versus-Host Disease. ( 27523006 )
2016
48
Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis. ( 27171228 )
2016
49
Deviation in the recovery of the lower limb and respiratory muscles of patients with polymyositis: a preliminary clinical study. ( 27799713 )
2016
50
HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis /Dermatomyositis with Interstitial Lung Disease. ( 27537498 )
2016

Variations for Polymyositis

Expression for Polymyositis

Search GEO for disease gene expression data for Polymyositis.

Pathways for Polymyositis

GO Terms for Polymyositis

Cellular components related to Polymyositis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.5 AARS EXOSC9 GARS IARS ICAM1 MB
2 aminoacyl-tRNA synthetase multienzyme complex GO:0017101 8.62 IARS KARS

Biological processes related to Polymyositis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 9.63 ICAM1 SFTPD VCAM1
2 response to hypoxia GO:0001666 9.61 ICAM1 MB VCAM1
3 response to amino acid GO:0043200 9.48 AARS ICAM1
4 leukocyte cell-cell adhesion GO:0007159 9.4 ICAM1 VCAM1
5 regulation of translational fidelity GO:0006450 9.37 AARS IARS
6 translation GO:0006412 9.35 AARS GARS HARS IARS KARS
7 response to copper ion GO:0046688 9.32 ICAM1 IL1A
8 membrane to membrane docking GO:0022614 9.26 ICAM1 VCAM1
9 diadenosine tetraphosphate biosynthetic process GO:0015966 9.16 GARS KARS
10 tRNA aminoacylation for protein translation GO:0006418 9.02 AARS GARS HARS IARS KARS

Molecular functions related to Polymyositis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.8 AARS CHKB GARS HARS IARS KARS
2 amino acid binding GO:0016597 9.37 AARS KARS
3 ligase activity GO:0016874 9.35 AARS GARS HARS IARS KARS
4 tRNA binding GO:0000049 9.33 AARS IARS KARS
5 aminoacyl-tRNA editing activity GO:0002161 9.26 AARS IARS
6 aminoacyl-tRNA ligase activity GO:0004812 9.02 AARS GARS HARS IARS KARS

Sources for Polymyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....